
Ten new amidrazone derivatives, comprising linear 2a-2e and 1,2,4-triazole derivatives 3a-3c, 3e-3f were obtained in reaction with cis-1,2,3,6-tetrahydrophthalic anhydride. The structures of the new compounds were confirmed by spectral analyses (1H NMR, 13C NMR and MS). Additionally, compound 3a was characterized by X-ray crystallography. All synthesized derivatives showed no cytotoxic effect against human peripheral blood mononuclear cells (PBMCs). Linear compounds exhibited significant antiproliferative effects on mitogen-stimulated T cells. Derivatives 2a-2c and cyclic compounds 3a, 3e and 3f effectively reduced TNF-α production more effectively than ibuprofen.All 1,2,4-triazole derivatives significantly enhanced IL-10 production whereas the linear compounds suppressed it. The novel amidrazone derivatives showed no antiproliferative activity against the A549 lung cancer cell line. The obtained 1,2,4-triazole derivatives may represent promising candidates in the search for new anti-inflammatory drugs.
The NLRP3 inflammasome is a critical innate immune sensor detecting diverse pathogen- and damage-associated molecular patterns (PAMPs/DAMPs). Its activation triggers the maturation and release of the proinflammatory cytokines IL-1β and IL-18, as well as pyroptotic cell death. Since dysregulated NLRP3 activity drives various autoinflammatory and metabolic diseases, it represents a major therapeutic target. This review provides an updated framework of NLRP3 activation mechanisms, emphasizing the roles of the NACHT and LRR domains in NEK7 recruitment and the PYD domain in ASC recruitment. We identify specific residues within these domains to guide docking-based studies. Furthermore, this review highlights the principal chemical scaffolds of emerging small-molecule NLRP3 inhibitors, both synthetic and natural products, with a focus on clinical candidates and pharmacological profiles. Special attention is given to plant-derived natural products as a source of NLRP3 drug discovery, which has expanded the inhibitor chemical space. Finally, we address future challenges, such as targeting upstream activation signals (e.g., ROS or oxidized DNA interactions), and designing dual inhibitors for multiple inflammasomes (e.g., AIM2, NLRP1, NLRC4) to mitigate inflammasome crosstalk. By integrating detailed mechanistic insights with therapeutic advances, this review aims to catalyze computational studies and accelerate the design of the next generation of safe and stable NLRP3-targeting therapeutics.
A series of novel bis(selenocyano)-functionalized steroidal derivatives were synthesized through structural modification of estrone and estradiol scaffolds. These compounds were systematically evaluated for their in vitro antiproliferative activity against a panel of human cancer cell lines. Additionally, antibacterial activities against drug-resistant strains such as MRSA and VRE were investigated. Among the tested compounds, 9d and 9e exhibited the most potent cytotoxic activity, with IC50 values reaching low-micromolar levels in several tumor models. Mechanistic studies revealed that 9d induces apoptosis in a concentration-dependent manner via early apoptotic pathways and triggers S-phase cell cycle arrest in SK-OV-3 cells. Molecular docking simulations suggested that 9c and 9d exhibit superior binding affinity toward tubulin at the colchicine-binding site compared to 2-methoxyestradiol (2-ME2), potentially through additional hydrogen-bonding interactions involving the selenocyanate groups. Antibacterial evaluation indicated selective activity against Gram-positive strains for 5-series and 9-series compounds, and highly active compounds include 5a, 5b and 9a (MIC = 8 μg mL−1 (MRSA), 16 μg mL−1 (VRE)), and 14c also emerged as a promising antibacterial lead against MRSA and VRE (MIC = 16 μg mL−1). However, all compounds were ineffective against Gram-negative bacteria (MIC >64 μg mL−1). This work establishes a robust structure–activity relationship (SAR) framework and highlights the potential of bis(selenocyano) on estrogenic frameworks as a promising strategy for developing multitargeted anticancer agents or antimicrobial agents.
We used the first reported allosteric antagonist of β2-adrenergic receptors (β2AR), Cmpd-15, as a lead compound. Employing the principles of scaffold hopping and bioisosterism, we designed and synthesized a series of indole amide derivatives. Allosteric antagonistic activity of these compounds on β2AR was assessed using a GloSensor™ cAMP accumulation assay, and a structure-activity relationship (SAR) analysis was carried out. Our findings revealed that the indole amide derivatives exhibited allosteric antagonism on the G protein signaling pathway of β2AR, effectively modulating the agonistic effect of the endogenous ligand isoproterenol (ISO) on β2AR. Notably, the allosteric activity of derivative M19 was 2.28 times that of the lead compound Cmpd-15, significantly expanding the structural diversity of the lead compound. Furthermore, the indole amide derivatives possess a simpler structural framework compared to Cmpd-15. Further investigation of the most active compound, M19, revealed that it exhibited no significant cytotoxicity. The solubility of M19 was superior to that of Cmpd-15, being approximately 7-fold higher. Moreover, M19 showed significantly improved metabolic stability in vitro compared with Cmpd-15. Collectively, M19 demonstrated markedly improved activity, drug-like properties, and safety profiles compared with Cmpd-15, highlighting its promising potential for further development.
Twenty-one phenothiazine–rhodanine derivatives (6a–g and 7a–n) were synthesized, characterized, and evaluated for aldose reductase (ALR2, AKR1B1) inhibition. Cellular effects were examined in HUVEC, A549, and Hep3B cells, alongside electronic-descriptor, ADME, and molecular-modeling analyses. Compound 7i showed the strongest ALR2 inhibition, with an apparent KI of 98.91 ± 9.58 nM, approximately 8.9-fold lower than that of epalrestat (877.80 ± 44.25 nM); this comparison requires independent confirmation. Matched-series analysis associated the highest potency with the combination of phenothiazine N-ethyl substitution and a 2-(diethylamino)-2-oxoethyl ester group. Cellular activity against A549 and Hep3B was generally limited, with no established mechanistic relationship to ALR2 inhibition. Docking reproduced the crystallographic ligand pose with an RMSD of 0.34 Å and suggested a plausible binding mode for 7i. MM-GBSA provided a protocol-dependent binding-energy estimate, while a single 500 ns molecular dynamics trajectory identified persistent protein–ligand contacts. Electronic descriptors did not show a robust, series-independent relationship with potency. Overall, 7i represents a potent biochemical hit requiring further validation and optimization. Its enzyme selectivity and normal-cell safety profile require further investigation, while high predicted lipophilicity and poor aqueous solubility indicate developability challenges.